ProMIS Neurosciences

Yahoo Finance • 28 days ago

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and f... Full story

Yahoo Finance • last month

European Dividend Stocks To Enhance Your Income Portfolio

As the pan-European STOXX Europe 600 Index experienced a slight decline, with mixed performances across major stock indexes such as Germany's DAX and France's CAC 40, investors are closely watching the European Central Bank's potential pol... Full story

Yahoo Finance • last month

After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance

(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc... Full story

Yahoo Finance • 2 months ago

ProMIS Neurosciences to execute 1-for-25 reverse stock split

* ProMIS Neurosciences (PMN [https://seekingalpha.com/symbol/PMN]) plans to implement a one-for-twenty-five reverse stock split of the company’s common shares on November 28, 2025. * The reverse stock split is intended to increase the... Full story

Yahoo Finance • 2 months ago

ProMIS Neurosciences Announces Reverse Stock Split

Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders,... Full story

Yahoo Finance • 3 months ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neu... Full story

Yahoo Finance • 4 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to repor... Full story

Yahoo Finance • 5 months ago

ProMIS Neurosciences GAAP EPS of -$0.29

* ProMIS Neurosciences press release [https://seekingalpha.com/pr/20199117-promis-neurosciences-announces-second-quarter-2025-financial-results-and-corporate-highlights] (NASDAQ:PMN [https://seekingalpha.com/symbol/PMN]): Q2 GAAP EPS of... Full story

Yahoo Finance • 6 months ago

ProMIS Neurosciences Announces Private Placement Financing

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting... Full story

Yahoo Finance • 6 months ago

ProMIS Neurosciences raises $3.2M through ATM offering, PIPE financing

* ProMIS Neurosciences (NASDAQ:PMN [https://seekingalpha.com/symbol/PMN]) has raised [https://seekingalpha.com/pr/20172913-promis-neurosciences-announces-0_8-million-registered-direct-offering-priced-at-the-market]$0.8 million at-the-mar... Full story

Yahoo Finance • 6 months ago

ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310

ProMIS Neurosciences Inc. (NASDAQ:PMN) announced Monday it has mutually agreed with BTIG, LLC to terminate its At The Market Offering Agreement, effective immediately. The agreement, originally established on January 5, 2024, allowed the c... Full story

Yahoo Finance • 6 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Opendoor Technologies Inc. 343,720,987 3.38 2.615 3.2042 +0.9542 TNF Pha... Full story

Yahoo Finance • 10 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

CAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic... Full story

Yahoo Finance • 10 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded pr... Full story

Yahoo Finance • 12 months ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded pro... Full story

Yahoo Finance • 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolde... Full story

Yahoo Finance • 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Raised $20.4 million in PIPE gross proceeds to support continued development of Company’s PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases Dosing of first subjects in first-in-human P... Full story

Yahoo Finance • 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeu... Full story

Yahoo Finance • 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfold... Full story

Yahoo Finance • 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS... Full story